A neuroendocrine tumor is a neoplasm which starts from cells of the nervous systems and endocrine. a lot of them are benign, whilst a few are malignant. It generally occurs in the intestine, and it is called as carcinoid tumors, however, they can also occur in the lung, pancreas also the rest of the body.
The worldwide market for neuroendocrine carcinoma is projected to foresee high growth over the forecast period to account for a market valuation of around US$ 2.5 Billion by 2027 end up from a valuation of US$ 1.5 Million in 2017. The overall market is estimated to increase by a strong 7.7% CAGR during the said period.
Based on region, the worldwide market is studied across the seven major regions, namely Latin America, North America, Eastern Europe, Western Europe, Japan, Asia Pacific excluding Japan and Middle East & Africa. APEJ and North America will be dominating the worldwide market for neuroendocrine carcinoma and will be highly lucrative throughout the forecasted period. Moreover, APEJ region is anticipated to increase at the maximum rate to record a strong 8.5% CAGR during the predicted period.
Based on the disease indication type, the overall market is segmented into gastric neuroendocrine tumors, lung neuroendocrine tumors, pancreatic neuroendocrine tumors and appendiceal neuroendocrine tumors. The gastric neuroendocrine tumors will be the biggest segment and are likely to reach a market value of US$ 1.2 Billion by the end of 2027. The lung neuroendocrine tumors are considered to be the second biggest segment in the worldwide market.
Based on the treatment type, the overall market is categorized into chemotherapy(natural products, alkylating agents, and antimetabolites), targeted therapy(tyrosine kinase inhibitors and mTOR inhibitors) and somatostatin analogs. The somatostatin analogs are projected to lead the worldwide market by accounting for a valuation of over US$ 1.5 Billion throughout the forecast period.
Based on the end user, the worldwide market is categorized as ambulatory surgery centres, oncology centres, clinics and hospital. The hospitals category is expected to the biggest category leading the worldwide market for neuroendocrine carcinoma registering a robust CAGR of 8.2% over the assessment period, owing to a surge in infrastructure investment in the direction of implementation of newer detection technologies. Clinics category is also likely to reflect huge potential during the conjecture time frame 2017-2027.
Key Market Players
Some major neuroendocrine carcinoma players operating in the worldwide market includes: Novartis AG, Pfizer Inc, Chiasma Inc, Abbvie Inc, Ipsen, Jubilant Life Sciences Ltd, Valeant Pharmaceuticals International Inc, Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd, Dauntless Pharmaceuticals Inc, Mateon Therapeutics Inc, Advanced Accelerator Applications, Isotopen Technologien München AGGlobal, Lexicon Pharmaceuticals Inc, Amgen Inc, Hutchison China MediTech Ltd, Mallinckrodt plc, Celgene Corporation
Request Report Sample@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1278